TWINSTRAND THERAPEUTICS INC has a total of 18 patent applications. Its first patent ever was published in 1997. It filed its patents most often in United States, EPO (European Patent Office) and Canada. Its main competitors in its focus markets pharmaceuticals, biotechnology and environmental technology are TRINITY THERAPEUTICS INC, MYELOS CORP and KEROS THERAPEUTICS INC.
# | Country | Total Patents | |
---|---|---|---|
#1 | United States | 10 | |
#2 | EPO (European Patent Office) | 3 | |
#3 | Canada | 2 | |
#4 | WIPO (World Intellectual Property Organization) | 2 | |
#5 | Australia | 1 |
# | Industry | |
---|---|---|
#1 | Pharmaceuticals | |
#2 | Biotechnology | |
#3 | Environmental technology |
# | Technology | |
---|---|---|
#1 | Medical preparations | |
#2 | Peptides | |
#3 | Climate change adaptation technologies | |
#4 | Therapeutic chemical compounds | |
#5 | Microorganisms |
# | Name | Total Patents |
---|---|---|
#1 | Borgford Thor | 18 |
#2 | Braun Curtis | 10 |
#3 | Purac Admir | 10 |
#4 | Stoll Dominik | 4 |
Publication | Filing date | Title |
---|---|---|
CA2560636A1 | Glycosylation variants of ricin-like proteins | |
US2005272048A1 | Ricin-like toxin variants for treatment of cancer, viral or parasitic infections | |
AU7636800A | Improved ricin-like toxins for treatment of cancer | |
US6531125B1 | Antiviral ricin-like proteins | |
US6803358B1 | Ricin-like toxin variants for treatment of cancer, viral or parasitic infections | |
EP0977862A2 | Ricin-like toxin variants for treatment of cancer, viral or parasitic infections | |
US6333303B1 | Antiviral ricin-like proteins |